Dimethylamine

Dimethylamine

SCHEMBL3686151

CNC.O=C(O)Cc1ccccn1

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.53
POLB P06746 1/20 0.53
RAB9A P51151 5/20 0.50
NPC1 O15118 4/20 0.50
LMNA P02545 3/20 0.50
HRH3 Q9Y5N1 1/20 0.50
PTPRA P18433 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
ALDH1A1 P00352 3/20 0.49
TAAR1 Q96RJ0 1/20 0.49
ALOX15 P16050 1/20 0.49
PTGDR2 Q9Y5Y4 1/20 0.48
KDM4E B2RXH2 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
GAA P10253 1/20 0.47
CYP1A2 P05177 1/20 0.47
TSHR P16473 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21298 0.92 PTPRA (0.56) SMN1; SMN2POLBRAB9ANPC1LMNA
Benzene SCHEMBL11747977 0.92 PTPRA (0.56) SMN1; SMN2POLBRAB9ANPC1LMNA
SCHEMBL29676689 0.92 PTPRA (0.56) SMN1; SMN2POLBRAB9ANPC1LMNA
Acetic Acid SCHEMBL27435803 0.91 CYP1A2 (0.53) SMN1; SMN2POLBRAB9ANPC1PTPRA
Iodide SCHEMBL2108436 0.90 PTPRA (0.55) SMN1; SMN2POLBRAB9ANPC1LMNA
Water SCHEMBL5531145 0.90 PTPRA (0.55) SMN1; SMN2POLBRAB9ANPC1LMNA
SCHEMBL988403 0.90 PTPRA (0.55) SMN1; SMN2POLBRAB9ANPC1LMNA
Water SCHEMBL29453010 0.90 PTPRA (0.55) SMN1; SMN2POLBRAB9ANPC1LMNA
Hydrochloric Acid SCHEMBL334937 0.90 PTPRA (0.55) SMN1; SMN2POLBRAB9ANPC1LMNA
Water SCHEMBL29453011 0.90 PTPRA (0.55) SMN1; SMN2POLBRAB9ANPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6028231-A Process for preparing 2-methyl-4-(2,2,3-trimethyl-cyclopent-3-en-1-yl)-but-2-en-1-ol HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 2000-02-22 US claimed
EP-1957437-B1 PROCESS FOR PRODUCING ALPHA,BETA-UNSATURATED ALDEHYDE COMPOUNDS KAO CORP (JP) 2017-05-03 EP disclosed
US-7732644-B2 Process for producing α,β-unsaturated aldehyde compounds KAO CORPORATION (JP) 2010-06-08 US disclosed
US-20090171124-A1 PROCESS FOR PRODUCING ALPHA, BETA-UNSATURATED ALDEHYDE COMPOUNDS KAO CORPORATION (JP) 2009-07-02 US disclosed
EP-1957437-A1 PROCESS FOR PRODUCING ALPHA,BETA-UNSATURATED ALDEHYDE COMPOUNDS Kao Corporation (JP) 2008-08-20 EP disclosed
WO-2007063703-A1 PROCESS FOR PRODUCING α,β-UNSATURATED ALDEHYDE COMPOUNDS KAO CORPORATION (JP) 2007-06-07 WO disclosed
US-7169749-B1 Aldol condensation carried out in an inert organic solvent, and reduction of the corresponding unsaturated aldehydes in the presence of copper/zinc catalysts, the process being carried out continuously under isothermal conditions in a narrow temperature range KAO CORPORATION (JP) 2007-01-30 US disclosed
EP-1212272-B1 METHOD FOR PRODUCING ALKYL-SUBSTITUTED BUTENOLS KAO CORP (JP) 2003-12-10 EP disclosed
WO-2001021568-A9 METHOD FOR PRODUCING ALKYL-SUBSTITUTED BUTENOLS COGNIS DEUTSCHLAND GMBH (DE) 2003-11-27 WO disclosed
EP-1212272-A1 METHOD FOR PRODUCING ALKYL-SUBSTITUTED BUTENOLS Cognis Deutschland GmbH & Co. KG (DE) 2002-06-12 EP disclosed
EP-0937018-B1 PROCESS FOR PREPARING 2-METHYL-4-(2,2,3-TRIMETHYL-CYCLOPENT-3-EN-1-YL)-BUT-2-EN-1-OL COGNIS DEUTSCHLAND GMBH (DE) 2001-08-29 EP disclosed
WO-2001021568-A1 METHOD FOR PRODUCING ALKYL-SUBSTITUTED BUTENOLS COGNIS DEUTSCHLAND GMBH & CO. KG (DE) 2001-03-29 WO disclosed
US-6028231-A Process for preparing 2-methyl-4-(2,2,3-trimethyl-cyclopent-3-en-1-yl)-but-2-en-1-ol HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 2000-02-22 US disclosed
EP-0937018-A1 PROCESS FOR PREPARING 2-METHYL-4-(2,2,3-TRIMETHYL-CYCLOPENT-3-EN-1-YL)-BUT-2-EN-1-OL Henkel Kommanditgesellschaft auf Aktien (DE) 1999-08-25 EP disclosed
WO-1998017613-A1 PROCESS FOR PREPARING 2-METHYL-4-(2,2,3-TRIMETHYL-CYCLOPENT-3-EN-1-YL)-BUT-2-EN-1-OL HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 1998-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090171124-A1 PROCESS FOR PRODUCING ALPHA, BETA-UNSATURATED ALDEHYDE COMPOUNDS ADH1C, ADH1A, ADH5 SMN1; SMN2 2919/4885POLB 985/4885RAB9A 3136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.